NasdaqGM - Nasdaq Real Time Price USD

Septerna, Inc. (SEPN)

6.69

-0.26

(-3.74%)

At close: May 9 at 4:00:00 PM EDT

6.69

0.00

(0.00%)

After hours: May 9 at 4:05:06 PM EDT

Septerna Insiders Placed Bullish Bets Worth US$934.3k

Over the last year, a good number of insiders have significantly increased their holdings in Septerna, Inc...

Simply Wall St. 16 days ago

SEPN
-3.74%
Wall Street Analysts Predict a 207.31% Upside in Septerna, Inc. (SEPN): Here's What You Should Know

The mean of analysts' price targets for Septerna, Inc. (SEPN) points to a 207.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks 25 days ago

SEPN
-3.74%
Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results

Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for Mast Cell Diseases, Expected to Initiate in 2025 Well-Capitalized with $420.8M Balance Sheet as of YE 2024 to Support Operating Runway into Early 2028 SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G prote

GlobeNewswire last month

SEPN
-3.74%
Septerna, Inc. (SEPN): Among Top Insider Purchases Last Month

We recently published a list of Top 10 Insider Purchases Last Month. In this article, we are going to take a look at where Septerna, Inc. (NASDAQ:SEPN) stands against other top insider purchases last month. Will there be a recession? How will new tariffs impact the U.S. economy? What’s next on President Trump’s geopolitical agenda? […]

Insider Monkey last month

SEPN
-3.74%
Septerna, Inc. (SEPN): Among The Stocks With At Least $30 Million In Insider Spending Recently

We recently compiled a list of the 10 Stocks With At Least $30 Million In Insider Spending Recently. In this article, we are going to take a look at where Septerna, Inc. (NASDAQ:SEPN) stands against the other stocks. We previously covered 10 stocks with at least $20 million in insider spending recently. Trump administration’s tariffs on […]

Insider Monkey 2 months ago

SEPN
-3.74%
Septerna to Present at TD Cowen 45th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna, will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 10:30 a.m. ET in Boston. About SepternaSepterna, Inc. is a biotechnology company pioneering a new era of GPCR d

GlobeNewswire 2 months ago

SEPN
-3.74%
Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist

Trial decision follows unanticipated events of elevated unconjugated bilirubin levels Company advancing multiple next-generation PTH1R agonists with distinct and unrelated chemical structures relative to SEP-786 SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of GPCR drug discovery, today announced its decision to discontinue the Phase 1 single- and multiple-ascending dose (SAD/MAD) clinical

GlobeNewswire 2 months ago

SEPN
-3.74%
‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public

The heads of three early-stage companies shared lessons from going public in a challenging market for biotech stocks.

BioPharma Dive 2 months ago

SEPN
-3.74%
Septerna, Inc. (SEPN): Among the Best Rebound Stocks to Invest In Now

We recently compiled a list of the 10 Best Rebound Stocks To Invest In Now. In this article, we are going to take a look at where Septerna, Inc. (NASDAQ:SEPN) stands against the other rebound stocks. The United States economy is in a constant state of flux. In recent weeks, moderated growth, evolving monetary policies, and […]

Insider Monkey 3 months ago

SEPN
-3.74%
Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotech company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Gil Labrucherie, CFA, J.D., as Chief Financial Officer. Mr. Labrucherie is a seasoned biopharma executive with more than 25 years of senior leadership experience in finance and legal roles for public biopharmaceutical and technology companies. “We are excited to w

GlobeNewswire 4 months ago

SEPN
-3.74%
Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 3:45 p.m. PT in San Francisco. A live webcast will be available in the Investors & Media section of the company’s website at www.septe

GlobeNewswire 4 months ago

SEPN
-3.74%
Septerna, Inc. Reports Q3 2024 Financials and Progress

Septerna, Inc. ( (SEPN) ) has released its Q3 earnings. Here is a breakdown of the information Septerna, Inc. presented to its investors. Septerna, Inc. is a clinical-stage biotechnology company focusing on the discovery and development of oral small molecule drugs targeting G protein-coupled receptors (GPCRs) for various therapeutic areas, including endocrinology, immunology, inflammation, and metabolic diseases. In its latest earnings report for the third quarter of 2024, Septerna highlighted

TipRanks 5 months ago

SEPN
-3.74%
Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small Molecule for Hypoparathyroidism, with Data Expected in Mid-2025 Well-Capitalized with Balance Sheet to Support a Planned Operating Runway into Second Half of 2027 SOUTH SAN FRANCISCO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a ne

GlobeNewswire 5 months ago

SEPN
-3.74%
Septerna initiated with an Overweight at JPMorgan

JPMorgan analyst Eric Joseph initiated coverage of Septerna (SEPN) with an Overweight rating and $38 price target Septerna represents a differentiated offering within broader biopharma, bringing predictive high-throughput screening and SAR optimization to the arena of G protein-coupled receptor targets, the analyst tells investors in a research note. The firm sees the company “executing a highly attractive pipeline strategy,” focused on validated targets in large established indications where an

TipRanks 5 months ago

SEPN
-3.74%
Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, today announced the closing of its upsized initial public offering (IPO) of 18,400,000 shares of its common stock at a public offering price of $18.00 per share, which includes an additional 2,400,000 shares issued upon the full exercise by the underwriters of their option

GlobeNewswire 6 months ago

SEPN
-3.74%
Septerna Prices Upsized Initial Public Offering

SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, today announced the pricing of its upsized initial public offering of 16,000,000 shares of its common stock at a public offering price of $18.00 per share. In addition, Septerna has granted the underwriters a 30-day option to purchase up to an additional 2,400,000 shares o

GlobeNewswire 6 months ago

SEPN
-3.74%

Performance Overview

Return	SEPN	S&P 500 (^GSPC)
YTD	-70.79%	-3.77%
1-Year	-71.53%	+8.55%
3-Year	-71.53%	+41.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Septerna, Inc. (SEPN)

Septerna Insiders Placed Bullish Bets Worth US$934.3k

Wall Street Analysts Predict a 207.31% Upside in Septerna, Inc. (SEPN): Here's What You Should Know

Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results

Septerna, Inc. (SEPN): Among Top Insider Purchases Last Month

Septerna, Inc. (SEPN): Among The Stocks With At Least $30 Million In Insider Spending Recently

Septerna to Present at TD Cowen 45th Annual Health Care Conference

Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist

‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public

Septerna, Inc. (SEPN): Among the Best Rebound Stocks to Invest In Now

Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer

Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Septerna, Inc. Reports Q3 2024 Financials and Progress

Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Septerna initiated with an Overweight at JPMorgan

Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering

Septerna Prices Upsized Initial Public Offering

Performance Overview